Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

PR today on Pralatrexate/Romidepsin in Relapsed/Refractory Lymphoid Malignancies. Had a 71% ORR in PTCL and a 33% ORR in non-PTCL in this Phase1/2 trial. Seventy-one % ORR in PTCL is pretty impressive. As single agents, pralatrexate, romidepsin, and belinostat have response rates ranging from 26%-29%. They will continue with the P2 portion of this trial in PTCL. Earlier results were previously presented but it doesn’t hurt to continue to spread the news. The median number of prior therapies was 3 (1-16). Geez, 16! If I was an onco doc (or the patient), I would be arguing with the insurance companies that it behooves them to pay for the initial expense of the 2 drugs in combo. That would be much cheaper than going through 16 prior therapies. Anyhows, impressive data for PTCL but come to think of it 33% ORR in non-PTCL might not be too shabby either but I am not sure regarding the statistics about that.

http://investor.sppirx.com/releasedetail.cfm?ReleaseID=1030595